Clinical Trials for Women’s Cancers

Clinical Trials for Women’s Cancers

The gynecologic oncology team at Froedtert & the Medical College of Wisconsin is involved with a nationwide group called the Gynecologic Oncology Group (GOG). This group consists of Gynecologic Oncologists, Medical Oncologists, Pathologists, Radiologists and many scientific researchers from around the world.

COGThe GOG is a non-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of Gynecologic malignancies. The Group is committed to maintaining the highest standards in clinical trials development, execution, analysis and distribution of results. Continuous evaluation of our processes is utilized in order to constantly improve the quality of patient care.

To promote this mission, the GOG receives support from the National Cancer Institute of the National Institutes for Health. Approximately 45 individual clinical trials are active at any one time within GOG for the patients with a variety of gynecologic malignancies, including cancers that arise from the ovaries, uterus, cervix, vagina, and vulva. General information on many of these trials for medical professionals and the lay public can be obtained from the NCI clinical trials database.

To obtain information regarding any gynecologic clinical trials that our department has open, please contact our research team at 1-855-771-9477 or Email Us.
Type of Cancer
Protocol ID & Study Title
Cervical or Pre-CancerCerGE
Women who have been treated for cervical cancer may be eligible for a current study on genetic susceptibility to that cancer. Exposure to the human papillomavirus (HPV) can lead to cervical cancer, but it doesn’t always.
CervicalGOG 263
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA, Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy

Keywords: Stage I/IIA Cervical Cancer
CervicalGOG 274
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: THE OUTBACK TRIAL

Keywords: Phase 3, Cervical Cancer, Chemotherapeutic Agent, Toxicity, Cognitive/Functional Effects, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity, Sexuality and Reproductive Issues, The Outback Trial
EndometrialGOG 258
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma

Keywords: Advanced Endometrial Carcinoma
EndometrialT Regulatory Cells and DNA Methylation in Early Endometrial Cancer Before and After Treatment

Keywords: Endometrial
OvarianGOG 186H
A RANDOMIZED PHASE II EVALUATION OF WEEKLY PACLITAXEL (NSC# 673089) VERSUS WEEKLY PACLITAXEL WITH ONCOLYTIC REOVIRUS (REOLYSIN NSC # 729968, BB-IND #13370) IN THE TREATMENT OF RECURRENT OR PERSISTENT OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER

Keywords: Recurrent, Fallopian tube, Ovarian Epithelial, Primary Peritoneal, Viral Therapy, Chemotherapy, Phase II
OvarianGOG 213
A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with Bevacizumab, followed by Bevacizumab and secondary cytoreduction surgery in platinum-sensitive, recurrent ovarian, fallopian tube and peritoneal primary cancer

Keywords: Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
OvarianGOG 225
Can Diet and Exercise Modulate Ovarian, Fallopian Tube or Peritoneal Cancer Progression-Free Survival?

Keywords: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Weight Change, Healthy Lifestyle
OvarianGOG 244
The Lymphedema and Gynecologic Cancer (LEG) Study: Incidence, Risk Factors, and Impact in Newly Diagnosed Patients

Keywords: Cervical Cancer, Endometrial Cancer, Vulvar Cancer, Lymphedema, Quality of Life
OvarianGOG 273
Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
OvarianGOG 3004
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy

Keywords:Olaparib, Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
OvarianGOG 9928
A Phase I Study of Intraperitoneal Egen-001 Administered in Combination with Pegylated Liposomal-Doxorubicin in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Keywords: Recurrent, Persistent, Epithelial Ovarian, Fallopian Tube, Primary Peritoneal
OvarianMERCK
A Study of MK-1775 in Combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin Alone in Adult Patients with Platinum Sensitive p53 Mutant Ovarian Cancer
UterineGOG 277
A Phase III Randomized Trial of Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma

Keywords: Uterine, Sarcoma, Leiomyosarcoma.
Type of Cancer
Protocol ID & Study Title
AllGOG 136
Tissue Bank: Acquisition of Human Gynecologic Specimens to be used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer
Cervical or Pre-CancerGOG 207
A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients with Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3)
Cervical or Pre-CancerGOG 219
A Phase III, Randomized Trial of Weekly Cisplatin and Radiation versus Cisplatin and Tirapazamine (IND# 46525) and Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervical Carcinoma Limited to the Pelvis
Cervical or Pre-CancerGOG 227E
Cervix: A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix
Cervical or Pre-CancerGOG 240
A Randomized Phase III Trial of Cisplatin plus Paclitaxel with and without Bevacizumab versus the Non-Platinum Doublet, Topotecan plus Paclitaxel, with and without Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix

Press Release

Keywords: Recurrent or Persistent Carcinoma of the Cervix
EndometrialGOG 86P
A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab, Paclitaxel/\Ccarboplatin/Temsirolimus and Ixabepilone/Carboplatin/ Bevacizumab as Initial Therapy for Measurable Stage III or IVA,, Stage IVB, or Recurrent Endometrial Cancer
EndometrialGOG 184
A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Cancer
EndometrialGOG 209
A Randomized Phase III Trial of Doxorubicin/ Cisplatin/ Paclitaxel/G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer
EndometrialGOG 249
A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma

Keywords: Early Stage Endometrial Cancer, Brachytherapy, Radiation Therapy
EndometrialGOG LAP 2
A Phase III Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling with Vaginal Hysterectomy and BSO versus Open Laparotomy with Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma, Clinical Stage I, IIA, Grade I, II, III 
EndometrialGenentech
Maggie: A Multicenter, Single-Arm, Open-Label, Phase II Study of GDC-0980 For the Treatment of Recurrent or Persistent Endometrial Carcinoma
OvarianGOG 182
A Phase III Randomized Trial of Paclitaxel and Carboplatin versus Triplet or Sequential Doublet Combinations in Patients with Epithelial Ovarian or Primary Peritoneal Carcinoma
OvarianGOG 212
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy

Keywords: Relapse in Women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
OvarianGOG 218
Ovarian and Primary Peritoneal: A Phase III Trial of Carboplatin and Paclitaxel plus Placebo versus Carboplatin and Paclitaxel plus Concurrent Bevacizumab (NSC #704865, IND# 7921) Followed by Placebo versus Carboplatin and Paclitaxel plus Concurrent and Extended Bevacizumab in Women with Newly Diagnosed, Previously Untreated, Stage III or IV, Epithelial Ovarian or Primary Peritoneal or Fallopian Tube Cancer
OvarianGOG 235
A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy

Keywords: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Tumor Marker
OvarianGOG 241
A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)

Keywords: Ovarian Mucinous Cystadenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Oxaliplatin
OvarianGOG 252
Ovarian: A Phase III Clinical Trial of Bevacizumab with IV versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma NCI-Supplied Agents(s): Bevacizumab (NSC #704865, IND# 7921)
OvarianGOG 267
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer

Keywords: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Quality of Life
OvarianGOG 268
A Phase II Evaluation of Temsirolimus in Combination with Carboplatin and Paclitaxel followed by Temsirolimus Consolidation as First-line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary

Keywords: Clear Cell Carcinoma of the Ovary
OvarianGOG 255
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate + OPT-821 Versus OPT-821 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer who are in Second or Third Complete Remission

Keywords: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Vaccine
OvarianGOG 261
A Randomized Phase III trial of Paclitaxel plus Carboplatin versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary

Keywords: Recurrent or Persistent Ovarian, Sarcoma
OvarianGOG 262
A Randomized Phase III Trila of every 3 weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination with Caboplatin with or without Concurrent and Consolidation Bevacizumab in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer

Keywords: Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer
OvarianGOG 272
Pilot Study of Standard Therapy for Prevention of Nausea Associated with First Line Post-operative Intraperitoneal Chemotherapy

Keywords: Stage II, III or IV Ovarian, Fallopian Tube, or Primary Peritoneal
OvarianGOG 3001
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, GOG 3001-Multi-Center Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers (Amgen Protocl #2010129)

Keywords: Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
OvarianGOG 3003
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 (IND#78,416) in Combination with Pegylated Liposomal Doxorubicin (PLD) in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Keywords: Recurrent, Persistent, Ovarian, Fallopian Tube, Primary Peritoneal
OvarianGOG 9927
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888) and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Keywords: Recurrent Ovarian, Primary Peritoneal, Fallopian Tube
OvarianAmgen 386 Study 20090508
A Phase 3, Randomized, Double-blind Trial of Paclitaxel Plus AMG 386 or Placebo in Women with Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers Following a Prior Platinum-Containing Regimen
Ovarian or Pre-cancerGOG 214
A Phase II Double Blind Randomized Trial Evaluating the Biologic Effect OF Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer

Keywords: High risk for Ovarian, Prevention